Abstract
Monoclonal antibodies (mAbs) and their derivatives are useful in therapeutic applications and as probes of the pathogenesis of acute and chronic inflammatory disorders. mAbs have been evaluated for treatment of a number of inflammatory disorders including sepsis/ systemic inflammatory response syndrome, Rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, diabetes, Crohn’s disease, acute transplant rejection, graft versus host disease, vascular ischemia and other disorders. The chapter provides a brief overview of each of the mAbs of interest and the latter section is divided into separate inflammatory disorders with more detailed descriptions of mAb therapies. Tumor necrosis factor has been implicated as a primary proinflammatory mediator involved in the pathogenesis of a variety of acute and chronic inflammatory disorders. Anti-platelet therapy is effective in preventing acute thromboembolic artery occlusion by inhibiting platelet activation. Combinations of mAbs have been evaluated in animal and human studies of acute and chronic inflammatory diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
